Understanding patient preferences for consultations on oral cancer drugs
Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital: Discrete Choice Method to Inform Decision-making by Healthcare Professionals
This study looks at what patients and their caregivers want from consultations about oral cancer medications to help them use these drugs safely and effectively.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT05970471 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the preferences of patients receiving oral anticancer medications and their informal caregivers regarding pharmaceutical consultations in a hospital setting. It focuses on ensuring safe usage of these drugs by providing patients with the necessary tools to manage adverse effects and improve compliance. The study employs a discrete-choice experiment (DCE) to gather insights into patient needs and expectations, thereby enhancing the pharmacist-patient relationship and overall care experience.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with lung, breast, prostate, or renal cancer who are receiving oral cancer medications.
Not a fit: Patients not receiving oral cancer drugs or those with other types of cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved patient engagement and safety in the management of oral cancer therapies.
How similar studies have performed: Other studies have successfully utilized discrete-choice experiments to assess patient preferences in healthcare settings, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
of patients: Main inclusion Criteria: * Patients with lung, prostate breast, prostate or renal cancer; * Patients with oral cancer drugs; * Patients accepted to take par in pharmaceutical consultation in hospital.
Where this trial is running
Besançon
- CHU de Besançon — Besançon, France (Recruiting)
Study contacts
- Principal investigator: Virginie NERICH, PhD — CHU de Besançon
- Study coordinator: Astrid POZET
- Email: apozet@chu-besancon.fr
- Phone: +33381218988
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.